Bristol Myers Squibb (CELG-RI) Finished Goods (2010 - 2013)
Bristol Myers Squibb (CELG-RI) posted quarterly Finished Goods of $569.0 million for Q1 2013, up 13.57% year-over-year from $501.0 million in Q1 2012, and down 0.52% quarter-over-quarter from $572.0 million in Q4 2012.
Bristol Myers Squibb (CELG-RI) Finished Goods (2010 - 2013) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Finished Goods for 4 consecutive years, with $569.0 million the latest figure, recorded in Q1 2013.
- In Q1 2013, Finished Goods rose 13.57% year-over-year to $569.0 million; the TTM figure through Mar 2013 stood at $569.0 million (up 13.57% YoY), while the FY2012 annual figure was $572.0 million, up 19.67% from the prior year.
- Finished Goods retreated to $569.0 million in Q1 2013 per CELG-RI's latest filing, from $572.0 million in the prior quarter.
- Across five years, Finished Goods topped out at $572.0 million in Q4 2012 and bottomed at $397.0 million in Q4 2010.
- Historically, Finished Goods has averaged $484.7 million across 4 years, with a median of $489.5 million in 2011.
- Annual changes were most pronounced in 2012 — Finished Goods rose 21.01% — and 2013, when it increased 13.57%.
- Bristol Myers Squibb's Finished Goods stood at $397.0 million in 2010, then rose by 20.4% to $478.0 million in 2011, then climbed by 19.67% to $572.0 million in 2012, then slipped by 0.52% to $569.0 million in 2013.
- Business Quant data shows CELG-RI's Finished Goods at $569.0 million in Q1 2013, $572.0 million in Q4 2012, and $533.0 million in Q3 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 569.00 Mn |
| Dec 31, 2012 | 572.00 Mn |
| Sep 30, 2012 | 533.00 Mn |
| Jun 30, 2012 | 503.00 Mn |
| Mar 31, 2012 | 501.00 Mn |
| Dec 31, 2011 | 478.00 Mn |
| Sep 30, 2011 | 443.00 Mn |
| Jun 30, 2011 | 437.00 Mn |
| Mar 31, 2011 | 414.00 Mn |
| Dec 31, 2010 | 397.00 Mn |